PITTSBURGH , Feb. 5, 2024 /PRNewswire/ -- PANTHERx ® Rare, a leader in rare disease product patient access and support services in the United States , is pleased to announce it was selected by Chiesi Global Rare Diseases, a business unit ...
SEATTLE , Jan. 30, 2024 /PRNewswire/ -- Sound Pharmaceuticals (SPI) will present the Phase 2b STOP Ototoxicity data that was selected for podium presentation at the Association for Research in Otolaryngology (ARO) Midwinter Meeting in ...
London, Jan. 30, 2024 (GLOBE NEWSWIRE) -- January 30, 2024, London, UK – OPEN Health has launched OPEN X Health , a new practice focused on providing data-driven creativity to the pharmaceutical industry. OPEN X Health (OPEN X) ...
In the Phase 2b trial, 100% (5 of 5) of ibezapolstat-treated patients who agreed to observation for up to three months following Clinical Cure of CDI experienced no recurrence of infection Further analyses will be forthcoming as data become ...
- SION-109 is a small molecule targeting the interface between the ICL4 region and the NBD1 domain of the CFTR protein; designed to complement the company's NBD1 modulator portfolio - - First subject dosed in Phase 1 clinical trial - ...
HANGZHOU and SHAOXING, China , Jan. 24, 2024 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") today announces dosing of the first patient in Phase III clinical trial of ASC40 (Denifanstat) for treatment of moderate to ...
NEW TAIPEI CITY , Jan. 23, 2024 /PRNewswire/ -- Caliway Biopharmaceuticals (Caliway) announces that Australian Bellberry HREC has approved Caliway's application to initiate CBL-514's Pivotal Phase 3 study (CBL-0301 Phase 3) for ...
PARAMUS, N.J. , Jan. 22, 2024 /PRNewswire/ -- NS Pharma, Inc. (NS Pharma), a subsidiary of Nippon Shinyaku Co., Ltd, announced today that the European Commission (EC) has granted orphan drug designation to NS-229, which is being developed ...
Synendos Therapeutics transitions to a clinical-stage biotech company developing innovative Endocannabinoid System (ECS) treatments for neuropsychiatric, neuroinflammatory and other Central Nervous System (CNS) disorders Clinical Trial ...
Orphalan announces China NMPA’s approval of its trientine tetrahydrochloride product for the treatment of Wilson disease Paris, France 18 January , 2024 - Orphalan SA (“Orphalan” or “the Company”), an international orphan drug ...
The immunotherapy-boosting drug N-803, with the brand name Anktiva, was granted approval by the U.S. Food and Drug Administration (FDA) on April 22, 2024, based on the positive outcome of a clinical trial ...
Biopharmaceutical companies are once again competing in the development of innovative drugs for metabolic dysfunction-associated steatohepatitis (MASH), after a series of failures faced by drug manufacturers. The US FDA approval of ...
A study was presented by the Gardy Health system in Atlanta, Georgia, US, at the 73rd Annual Scientific Session of the American College of Cardiology. The study was conducted to evaluate the frequency of heart failure hospitalizations (HFH) in ...
Generic drugs and Branded drugs are essentially the same, as they both have the same active ingredient. Generic drugs can provide the same therapeutic advantages as branded drugs at a reduced cost, as they do not have to undergo extensive ...
Melanoma is an extremely fatal form of skin cancer and has inherent resistance to both radiotherapy and chemotherapy ( ). The occurrence of Melanoma has been increasing steadily and become a major health issue since the 5-year ...
Subscribe to our Free Newsletters!
Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment.
Full Disclaimer
Advertise with us | Medindia Copyright | Privacy Policy | Terms of Use © All Rights Reserved 1997 - 2024
Careers